Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sansure BiotechSHSE:688289 -2.28%67 Return-on-Tangible-Equity is 3.48% as of Mar. 2026, which is 32% below its 10-year median of 5.09. GuruFocus rates SHSE:688289 with a GF Score™ of 67/100 and a GF Value™ of ¥20.98 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 758 Medical Devices & Instruments companies, Sansure Biotech ranks worse than 53.69% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sansure Biotech's annualized net income for the quarter that ended in Mar. 2026 was ¥199 Mil. Sansure Biotech's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ¥5,723 Mil. Therefore, Sansure Biotech's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 3.48%.
The historical rank and industry rank for Sansure Biotech's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:688289'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -2.89 Med: 5.09 Max: 99.49
Current: 2.71
During the past 9 years, Sansure Biotech's highest Return-on-Tangible-Equity was 99.49%. The lowest was -2.89%. And the median was 5.09%.
SHSE:688289's Return-on-Tangible-Equity is ranked worse than 53.69% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs SHSE:688289: 2.71
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sansure Biotech Return-on-Tangible-Equity Related Terms
Sansure Biotech Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sansure Biotech's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688289 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, Sansure Biotech's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sansure Biotech Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sansure Biotech's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sansure Biotech's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 3.48% mean?
Sansure Biotech (SHSE:688289) has a Return-on-Tangible-Equity of 3.48% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sansure Biotech and its competitors. This is 32% below median its historical median of 5.09. According to the industry distribution chart, Sansure Biotech ranks #407 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 53.7%.
Is Sansure Biotech's Return-on-Tangible-Equity too high?
Sansure Biotech's current Return-on-Tangible-Equity of 3.48% is 32% below median its 10-year median of 5.09. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.06. Sansure Biotech's value of 3.48% is 14.2% below this industry median. Based on the distribution chart, Sansure Biotech ranks #407 out of 758 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Sansure Biotech has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sansure Biotech's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sansure Biotech ranks #407 out of 758 companies for Return-on-Tangible-Equity. This places Sansure Biotech in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.06. Sansure Biotech's value of 3.48% is 14.2% below this benchmark. While the company's 10-year median is 5.09 vs. the industry median of 4.06, Sansure Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sansure Biotech's current Return-on-Tangible-Equity of 3.48% is 14.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sansure Biotech and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sansure Biotech's current Return-on-Tangible-Equity is 3.48%, which is 32% below median its own 10-year median of 5.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sansure Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sansure Biotech (SHSE:688289) is currently considered Possible Value Trap. The stock's GF Value™ is ¥20.98, compared to a current price of ¥14.56 — trading 30.6% below its estimated fair value. The current Return-on-Tangible-Equity is 3.48%, which is 32% below median its 10-year median of 5.09 and 14.2% below the Medical Devices & Instruments industry median of 4.06. Sansure Biotech's overall GF Score™ is 67/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sansure Biotech (SHSE:688289), the current Return-on-Tangible-Equity is 3.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sansure Biotech (SHSE:688289) Overvalued in 2026?
Based on GuruFocus' analysis, Sansure Biotech stock appears to be undervalued.
The current stock price of ¥14.56 is trading 30.6% below its estimated GF Value™ of ¥20.98.
GuruFocus considers Sansure Biotech to be Possible Value Trap.
Key valuation signals for SHSE:688289:
Return-on-Tangible-Equity: 3.48% (32% below median its 10-year median of 5.09)
GF Value™: ¥20.98 vs. price of ¥14.56 (30.6% below fair value)
Industry Position: 14.2% below the Medical Devices & Instruments median (#407 of 758)
No single metric tells the full story. See the SHSE:688289 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688289 has been successfully added to your 
